Sign in Subscribe

Archive

A collection of 370 issues

Latest

RAS and BRAF mutations may predict different immunotherapy outcomes in MSI-H/dMMR metastatic CRC

Skip to content The CRC Digest ◇ RESEARCH RAS and BRAF mutations may predict different immunotherapy outcomes in MSI-H/dMMR metastatic CRC A meta-analysis found that oncogenic driver mutations like RAS and BRAF may contribute to clinically meaningful differences in how MSI-H/dMMR metastatic colorectal cancer responds to immune checkpoint inhibitors,

Expert Consensus Calls for Sex and Gender-Tailored CRC Screening

Skip to content The CRC Digest Expert Consensus Calls for Sex and Gender-Tailored CRC Screening An Italian consensus study from the AIOM-GISEG working group identified areas of expert agreement regarding the potential appropriateness and clinical relevance of sex and gender-tailored colorectal cancer screening strategies, noting that despite evidence of sex

CT-Based Imaging Biomarker May Predict MSI Status

Skip to content The CRC Digest CT-Based Imaging Biomarker May Predict MSI Status A retrospective study of 121 CRC patients investigated whether CT-derived extracellular volume fraction can predict microsatellite instability status non-invasively. (American Journal of Translational Research) This content is informational only and does not constitute medical advice. Always consult

Gut Microbiota Differs Between MSI-H and MSS Colorectal Cancer

Skip to content The CRC Digest Gut Microbiota Differs Between MSI-H and MSS Colorectal Cancer A study collected fecal samples from CRC patients with different microsatellite states and healthy individuals to explore differences in gut microbiota between MSI-H and MSS colorectal cancer, potentially providing new directions for immunotherapy in MSS

Latent Profile Analysis Identifies Distinct Quality of Life Patterns in CRC Survivors

Skip to content The CRC Digest Latent Profile Analysis Identifies Distinct Quality of Life Patterns in CRC Survivors Researchers used latent profile analysis of EORTC quality of life questionnaires to identify distinct health-related quality of life profiles among colorectal cancer patients, aiming to inform more personalized follow-up strategies. (Colorectal Disease)

Patient-Provider Relationship Quality Linked to Screening Uptake

Skip to content The CRC Digest Patient-Provider Relationship Quality Linked to Screening Uptake A national study using HINTS data from 7,732 US adults aged 45-75 found that patient-provider relationship quality may influence colorectal cancer screening uptake. (Cureus) This content is informational only and does not constitute medical advice. Always

Systematic Review Examines CRC Screening Uptake in People Living With HIV

Skip to content The CRC Digest Systematic Review Examines CRC Screening Uptake in People Living With HIV A systematic review and meta-analysis synthesized evidence on colorectal cancer screening uptake and lesion detection rates in people living with HIV, including comparisons with HIV-negative controls. (HIV Medicine) This content is informational only

Phase Ib FIERCE Study Assesses Trifluridine/Tipiracil With Radiation in Rectal Cancer

Skip to content The CRC Digest ◆ TRIAL DATA Phase Ib FIERCE Study Assesses Trifluridine/Tipiracil With Radiation in Rectal Cancer A phase Ib study to assess the safety of neoadjuvant trifluridine/tipiracil combined with concurrent radiation in patients with resectable stage II/III rectal cancer. (Clinical Colorectal Cancer) This content

Mitochondrial Metabolism Drives 5-FU Resistance in Colorectal Cancer

Skip to content The CRC Digest ◇ RESEARCH Mitochondrial Metabolism Drives 5-FU Resistance in Colorectal Cancer Preclinical research shows that 5-fluorouracil treatment promotes mitochondrial biogenesis and increased mitochondrial function in surviving colorectal cancer cells, and that targeting mitochondrial metabolism—particularly Complex I inhibition—can sensitize CRC cells to chemotherapy. (Nature Metabolism)

Copanlisib Plus Nivolumab Combination Fails to Meet Response Endpoint in MSS Colorectal Cancer

Skip to content The CRC Digest ◆ TRIAL DATA Copanlisib Plus Nivolumab Combination Fails to Meet Response Endpoint in MSS Colorectal Cancer A phase 1/2 trial testing copanlisib (a PIK3CA inhibitor) combined with nivolumab in metastatic microsatellite stable CRC did not meet its primary endpoint, with 0 of 17 PIK3CA-wildtype